Literature DB >> 29397723

Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites.

Chelliah Selvam1, Isabelle A Lemasson1, Isabelle Brabet2, Nadia Oueslati2, Berin Karaman1, Alexandre Cabaye1, Amélie S Tora2, Bruno Commare1,3, Tiphanie Courtiol1, Sara Cesarini1, Isabelle McCort-Tranchepain1, Delphine Rigault1, Laetitia Mony1,4, Thomas Bessiron5, Heather McLean5, Frédéric R Leroux3, Françoise Colobert3, Hervé Daniel5, Anne Goupil-Lamy6, Hugues-Olivier Bertrand6, Cyril Goudet2, Jean-Philippe Pin2, Francine C Acher1.   

Abstract

A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an l-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu4 subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29397723     DOI: 10.1021/acs.jmedchem.7b01438

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Authors:  Joseph D Panarese; Darren W Engers; Yong-Jin Wu; Joanne J Bronson; John E Macor; Aspen Chun; Alice L Rodriguez; Andrew S Felts; Julie L Engers; Matthew T Loch; Kyle A Emmitte; Arlindo L Castelhano; Michael J Kates; Michael A Nader; Carrie K Jones; Anna L Blobaum; P Jeffrey Conn; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2018-10-16       Impact factor: 4.345

Review 2.  Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.

Authors:  Nicole M Fisher; Mabel Seto; Craig W Lindsley; Colleen M Niswender
Journal:  Front Mol Neurosci       Date:  2018-10-23       Impact factor: 5.639

3.  A Light-Controlled Allosteric Modulator Unveils a Role for mGlu4 Receptors During Early Stages of Ischemia in the Rodent Cerebellar Cortex.

Authors:  Simon Bossi; Romain Helleringer; Micaela Galante; Ester Monlleó; Ana Trapero; Xavier Rovira; Hervé Daniel; Amadeu Llebaria; Heather McLean
Journal:  Front Cell Neurosci       Date:  2018-11-27       Impact factor: 5.505

4.  Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.

Authors:  Nicole M Fisher; Mabel Seto; Craig W Lindsley; Colleen M Niswender
Journal:  Front Mol Neurosci       Date:  2018-12-14       Impact factor: 5.639

5.  Conformational pathway provides unique sensitivity to a synaptic mGluR.

Authors:  Chris H Habrian; Joshua Levitz; Vojtech Vyklicky; Zhu Fu; Adam Hoagland; Isabelle McCort-Tranchepain; Francine Acher; Ehud Y Isacoff
Journal:  Nat Commun       Date:  2019-12-05       Impact factor: 14.919

Review 6.  Allosteric Molecular Switches in Metabotropic Glutamate Receptors.

Authors:  Zoltán Orgován; György G Ferenczy; György M Keserű
Journal:  ChemMedChem       Date:  2020-08-25       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.